Literature DB >> 31128571

A high C-reactive protein/procalcitonin ratio predicts Mycoplasma pneumoniae infection.

Olivia L Neeser1, Tanja Vukajlovic2,3, Laetitia Felder2,3, Sebastian Haubitz2,4, Angelika Hammerer-Lercher5, Cornelia Ottiger5, Beat Mueller2,3, Philipp Schuetz2,3, Christoph A Fux6.   

Abstract

Background Discriminating Mycoplasma pneumoniae (MP) from Streptococcus pneumoniae (SP) and viral etiologies of community-acquired pneumonia (CAP) is challenging but has important implications regarding empiric antibiotic therapy. We investigated patient parameters upon hospital admission to predict MP infection. Methods All patients hospitalized in a tertiary care hospital between 2013 and 2017 for CAP with a confirmed etiology were analyzed using logistic regression analyses and area under the receiver operator characteristics (ROC) curves (AUC) for associations between demographic, clinical and laboratory features and the causative pathogen. Results We analyzed 568 patients with CAP, including 47 (8%) with MP; 152 (27%) with SP and 369 (65%) with influenza or other viruses. Comparing MP and SP by multivariate logistic regression analysis, younger age (odds ration [OR] 0.56 per 10 years, 95% CI 0.42-0.73), a lower neutrophil/lymphocyte ratio (OR 0.9, 0.82-0.99) and an elevated C-reactive protein/procalcitonin (CRP/PCT) ratio (OR 15.04 [5.23-43.26] for a 400 mg/μg cut-off) independently predicted MP. With a ROC curve AUC of 0.91 (0.80 for the >400 mg/μg cutoff), the CRP/PCT ratio was the strongest predictor of MP vs. SP. The discriminatory value resulted from significantly lower PCT values (p < 0.001) for MP, while CRP was high in both groups (p = 0.057). Comparing MP and viral infections showed similar results with again the CRP/PCT ratio providing the best information (AUC 0.83; OR 5.55 for the >400 mg/μg cutoff, 2.26-13.64). Conclusions In patients hospitalized with CAP, a high admission CRP/PCT ratio predicts M. pneumoniae infection and may improve empiric management.

Entities:  

Keywords:  M. pneumoniae; biomarker; community acquired pneumonia; procalcitonin; respiratory infections

Mesh:

Substances:

Year:  2019        PMID: 31128571     DOI: 10.1515/cclm-2019-0194

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  4 in total

1.  Improved Diagnostics Help to Identify Clinical Features and Biomarkers That Predict Mycoplasma pneumoniae Community-acquired Pneumonia in Children.

Authors:  Patrick M Meyer Sauteur; Selina Krautter; Lilliam Ambroggio; Michelle Seiler; Paolo Paioni; Christa Relly; Riccarda Capaul; Christian Kellenberger; Thorsten Haas; Claudine Gysin; Lucas M Bachmann; Annemarie M C van Rossum; Christoph Berger
Journal:  Clin Infect Dis       Date:  2020-10-23       Impact factor: 9.079

2.  Serum amyloid a, C-reactive protein, and procalcitonin levels in children with Mycoplasma pneumoniae infection.

Authors:  Yuanyuan Jiang; Wenyang Wang; Zhijun Zhang; Xianfen Ma; Yanyan Sang; Jin Wang; Guoxiang Xu; Qiang Feng; Shuping Zhao
Journal:  J Clin Lab Anal       Date:  2022-02-11       Impact factor: 2.352

3.  Novel Functional eQTL-SNPs Associated With Susceptibility to Mycoplasma pneumoniae Pneumonia in Children.

Authors:  Yang Dong; Yanmin Gao; Cheng Luo; Nengshun Wu; Zhounan Cheng; Anni Qiu; Yan Zhou; Wendi Zhang; Minjie Chu; Qing Chang
Journal:  Front Public Health       Date:  2022-06-28

4.  The Etiology of Community-Acquired Pneumonia Correlates with Serum Inflammatory Markers in Children.

Authors:  August Wrotek; Julita Robakiewicz; Katarzyna Pawlik; Patryk Rudzinski; Izabela Pilarska; Aleksandra Jaroń; Aleksandra Imiełowska; Małgorzata Jarzębowska; Katarzyna Zabłocka; Teresa Jackowska
Journal:  J Clin Med       Date:  2022-09-20       Impact factor: 4.964

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.